“Deep Dive Debate” | After Achieving pCR with Immunotherapy in TNBC, Should Adjuvant Immunotherapy Be Continued or Stopped?
With the success of landmark clinical studies such as KEYNOTE-522, neoadjuvant treatment for early-stage triple-negative breast cancer (TNBC) has fully entered the era of immunotherapy combined with chemotherapy. While this strategy has significantly improved pathological complete response (pCR) rates and delivered substantial survival benefits, it has also raised one of the most debated questions in current clinical practice:









